It has recently been shown that captopril may show antirheumatoid activity.' Captopril improved both clinical and laboratory measurements of disease activity in a manner similar to that of Dpenicillamine, with which captopril also shares similarities in chemical structure, metabolism, and side effects.
Captopril is an inhibitor of angiotensin converting enzyme (ACE), which converts the inactive decapeptide angiotensin I to the active octapeptide angiotensin II. In 
Patients and methods

PATIENTS AND SAMPLES
Venous blood samples (5 ml clotted) were taken from 48 patients with active RA (American Rheumatism Association (ARA) criteria), and when a significant synovial effusion was also present a specimen of synovial fluid was withdrawn (19 patients). Simultaneous serum and SF samples were also obtained from 11 patients with OA, and serum samples from 24 patients with ankylosing spondylitis (AS) (New York criteria), 12 patients with psoriatic arthritis, and 20 patients with Behcet's syndrome (Japanese criteria). These groups of patients were receiving various drugs at the time of sampling, primarily non-steroidal anti-inflammatory agents, but not antihypertensive drugs or antirheumatoid drugs. These samples were compared with those from 26 healthy controls who were free of all medication, including antihypertensive drugs, at the time of sampling. Baseline serum samples and samples after 24 weeks' treatment with captopril (-150 mg/day) from 11 patients with active RA were also analysed for ACE activity, together with samples from nine controls treated for 24 weeks with sulphasalazine (2.0 g/day).
All SF samples were collected in plain tubes. In each case 50% of the sample was stored without centrifugation. The remaining 50% was centrifuged at 2000 rpm for 10 min and stored in a separate plain tube.
ASSAYS
All samples were analysed for ACE activity by the spectrophotometric method of Pre and Bladier. 8 One unit of ACE activity was defined as the amount of enzy-me releasing 1 iimol hippurate/min/l of serum or SF under the described reaction conditions. ACE was measured with an intra-assay precision of + 11-4%. One freeze/thaw cycle did not notably affect serum or centrifuged SF results, but there was a marked difference in results for uncentrifuged SF. The assay could, therefore, be done on samples stored at -20°C.
Total protein concentrations were also determined for paired serum All SF samples and their matched sera were assayed for total protein in order to express ACE activity per unit of protein in addition to the absolute ACE activity. When uncentrifuged SF was compared with centrifuged SF after one freeze/thaw cycle for the RA samples (n=19) two patients had' higher ACE levels in the uncentrifuged SF, but nine results for the latter had fallen to 5 U/I. This comparison and a comparison of SF (centrifuged) with serum ACE is shown in Table 2 . Absolute ACE activity was greater in serum (median=50 U/l) than in SF (median=30 U/l), but was similar when corrected for protein (median=0-67 U/g in both fluids). Absolute ACE activity in the 11 OA samples showed lower SF (centrifuged) levels than seen in the RA samples (OA median=18 U/l, p<0-01), but when corrected for protein levels there was no significant difference between the two diseases (OA median=0-61 U/g). The 11 patients with RA treated with captopril for 24 weeks showed a marked increase in measured ACE activity (Table 3) . Absolute ACE activity increased in 10 patients, but when corrected for protein levels all 11 patients showed an increase (p<0.01). The baseline ACE levels for these patients did not correlate significantly with accepted measures of disease activity, including the Al, CS, ESR, or CRP (Table 4a) . Although ESR and CRP correlated well with one another, neither correlated well with Al (Table 4b ). The correlations after 24 weeks of treatment were better and suggested a weak relationship between acute phase reactants and ACE levels, though not between clinical mea- 
